Nuclear Medicine and Biology
These multidisciplinary studies should validate the mechanism of localization whether the tracer is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the tracer to changes in disease or treatment, although studies validating mechanism alone are acceptable as well.
If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized and should provide a substantial improvement over existing methodologies.
Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
Further Information on the Aims and Scope of Nuclear Medicine and Biology
Graphical abstract A Graphical Abstracts is mandatory for this journal, please find more details here.
Introduction In keeping with the goal of translating the preclinical studies to the clinic, the introduction of your manuscript should contain the potential impact of the tracer on a particular disease.
Materials and Methods Given that validation of new targeted radiotracers is a primary goal of the journal, all new tracers should minimally have radiochemical yield (RCY), radiochemical purity (RCP), molar activity (MA), for reference see the publication Consensus nomenclature rules for radiopharmaceutical chemistry-Setting the record straight. If not commercially available, for small molecules and peptides the precursor and cold reference should have identity (minimally 1H-NMR, 13C-NMR, HRMS) and purity (minimally HPLC) reported, while for metal complexes and biologicals alternative analyses should be provided.
Identity of a new tracer is crucial information and should be assessed via minimally HPLC where the retention time is compared to a cold reference (e.g. 19F analog of the 18F tracer). In case a radionuclide does not have a stable isotope available, a surrogate element should be used instead (e.g. Re to use as surrogate of 99mTc).
In vivo evaluation of new tracer should minimally include assessment of the biodistribution and the metabolism of a new tracer, if not applicable this should be justified in the discussion of the manuscript.
All metrics should have an associated average value, standard deviation and number of studies. For small-animal images, the amount injected, the anesthesia used and the image duration should minimally be included in the figure caption so comparisons can be easily made. Correlation with tissue dissection data is recommended.
Manuscripts on pharmacy including those on automation that focus on the apparatus and the computer program should present substantially improved RCY, RCP, MA; shorter reaction time; or improved analytical techniques compared to the present state of the art. All new pharmacy approaches should be referenced as complying with standard applicable regulations Radiation-absorbed dose (dosimetry) studies in humans should contain the full data set published as supplementary data. A comparison with small-animal dosimetry data is encouraged.
These multidisciplinary studies should validate the mechanism of localization whether the tracer is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the tracer to changes in disease or treatment, although studies validating mechanism alone are acceptable as well.
If the synthesis of a new radiopharmaceutical is submitted without
Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
Further Information on the Aims and Scope of Nuclear Medicine and Biology
Graphical abstract A Graphical Abstracts is mandatory for this journal, please find more details here.
Introduction In keeping with the goal of translating the preclinical studies to the clinic, the introduction of your manuscript should contain the potential impact of the tracer on a particular disease.
Materials and Methods Given that validation of new targeted radiotracers is a primary goal of the journal, all new tracers should minimally have radiochemical yield (RCY), radiochemical purity (RCP), molar activity (MA), for reference see the publication Consensus nomenclature rules for radiopharmaceutical chemistry-Setting the record straight. If not commercially available, for small molecules and peptides the precursor and cold reference should have identity (minimally 1H-NMR, 13C-NMR, HRMS) and purity (minimally HPLC) reported, while for metal complexes and biologicals alternative analyses should be provided.
Identity of a new tracer is crucial information and should be assessed via minimally HPLC where the retention time is compared to a cold reference (e.g. 19F analog of the 18F tracer). In case a radionuclide does not have a stable isotope available, a surrogate element should be used instead (e.g. Re to use as surrogate of 99mTc).
In vivo evaluation of new tracer should minimally include assessment of the biodistribution and the metabolism of a new tracer, if not applicable this should be justified in the discussion of the manuscript.
All metrics should have an associated average value, standard deviation and number of studies. For small-animal images, the amount injected, the anesthesia used and the image duration should minimally be included in the figure caption so comparisons can be easily made. Correlation with tissue dissection data is recommended.
Manuscripts on pharmacy including those on automation that focus on the apparatus and the computer program should present substantially improved RCY, RCP, MA; shorter reaction time; or improved analytical techniques compared to the present state of the art. All new pharmacy approaches should be referenced as complying with standard applicable regulations Radiation-absorbed dose (dosimetry) studies in humans should contain the full data set published as supplementary data. A comparison with small-animal dosimetry data is encouraged.
